ingenol mebutate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4226 75567-37-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • picato
  • PEP005
  • Ingenol 3-angelate
  • 3-Angeloylingenol
  • 3-Ingenyl angelate
  • ingenol mebutate
protein kinase C agonist and antineoplastic
  • Molecular weight: 430.54
  • Formula: C25H34O6
  • CLOGP: 2.89
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 104.06
  • ALOGS: -3.19
  • ROTB: 4

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2012 FDA LEO PHARMA AS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site vesicles 796.77 120.17 111 1109 1244 50602660
Application site erythema 683.78 120.17 114 1106 4424 50599480
Application site pain 457.75 120.17 79 1141 3719 50600185
Incorrect product administration duration 447.34 120.17 89 1131 9186 50594718
Product administered at inappropriate site 254.64 120.17 45 1175 2398 50601506
Application site scab 251.35 120.17 32 1188 160 50603744
Application site swelling 244.74 120.17 35 1185 463 50603441
Application site exfoliation 179.05 120.17 25 1195 274 50603630
Application site discharge 159.32 120.17 21 1199 143 50603761
Application site pustules 134.70 120.17 15 1205 14 50603890
Application site reaction 129.65 120.17 21 1199 653 50603251

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site erythema 283.10 197.12 46 484 2053 29571944

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site erythema 528.36 127.88 87 972 4602 64493071
Application site vesicles 441.25 127.88 63 996 1259 64496414
Application site pain 395.36 127.88 67 992 4181 64493492
Incorrect product administration duration 309.42 127.88 62 997 9696 64487977
Application site scab 260.99 127.88 32 1027 177 64497496
Application site exfoliation 237.58 127.88 31 1028 300 64497373
Product administered at inappropriate site 214.01 127.88 38 1021 3072 64494601
Squamous cell carcinoma of skin 206.52 127.88 46 1013 11830 64485843
Application site swelling 193.16 127.88 28 1031 614 64497059
Application site pustules 147.42 127.88 16 1043 20 64497653
Squamous cell carcinoma 136.98 127.88 34 1025 13835 64483838

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D06BX02 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
CHEMOTHERAPEUTICS FOR TOPICAL USE
Other chemotherapeutics
FDA PE N0000009176 Increased Cellular Death
FDA EPC N0000184015 Cell Death Inducer
CHEBI has role CHEBI:35610 antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Actinic keratosis indication 201101007 DOID:8866




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.14 acidic
pKa2 11.74 acidic
pKa3 13.75 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 8536163 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 8716271 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 8735375 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 9820959 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 9861603 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 8536163 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 8716271 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 8735375 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 9820959 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.05% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 9861603 Dec. 18, 2026 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
0.015% PICATO LEO LABS N202833 Jan. 23, 2012 DISCN GEL TOPICAL 9789078 May 15, 2033 TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Protein kinase C delta type Kinase ACTIVATOR EC50 8.33 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Protein kinase C gamma type Kinase ACTIVATOR Ki 9.79 IUPHAR
Protein kinase C beta type Kinase EC50 6.84 SCIENTIFIC LITERATURE
Protein kinase C alpha type Kinase EC50 6.20 SCIENTIFIC LITERATURE
Protein kinase C epsilon type Kinase EC50 8.96 SCIENTIFIC LITERATURE
Serine/threonine-protein kinase D1 Kinase EC50 7.52 SCIENTIFIC LITERATURE

External reference:

IDSource
D09393 KEGG_DRUG
4031406 VANDF
4031407 VANDF
CHEBI:66913 CHEBI
WUD PDB_CHEM_ID
CHEMBL1863513 ChEMBL_ID
C486592 MESH_SUPPLEMENTAL_RECORD_UI
C008125 MESH_SUPPLEMENTAL_RECORD_UI
7443 IUPHAR_LIGAND_ID
9006 INN_ID
30220-46-3 SECONDARY_CAS_RN
DB05013 DRUGBANK_ID
7686S50JAH UNII
6918670 PUBCHEM_CID
442042 PUBCHEM_CID
1242806 RXNORM
187013 MMSL
28281 MMSL
014146 NDDF
710279008 SNOMEDCT_US
715552008 SNOMEDCT_US
C2825682 UMLSCUI
C0063537 UMLSCUI
CHEMBL2165402 ChEMBL_ID
IC77UZI9G8 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Picato HUMAN PRESCRIPTION DRUG LABEL 1 50222-502 GEL 150 ug TOPICAL NDA 26 sections
Picato HUMAN PRESCRIPTION DRUG LABEL 1 50222-503 GEL 500 ug TOPICAL NDA 26 sections